grant

Tissue Engineering Strategies to Revitalize Allografts

Organization UNIVERSITY OF OREGONLocation EUGENE, UNITED STATESPosted 1 Jul 2023Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY20251,2-Ethanediol2-HydroxyethanolANG1ANG1 GeneANGPT1ANGPT1 geneAbscissionAdenoviridaeAdenovirusesAdhesionsAdhesivesAllograftingAngiopoietin 1 GeneAngiopoietin-1AutograftAutologous TransplantationAutotransplantBiochemicalBiomechanicsBlood VesselsBody TissuesBone GraftingBone RegenerationBone TransplantationCLG4CLG4ACXCL12CXCL12 geneCXCL12 proteinCell BodyCell Migration AssayCell TransplantationCellsChemistryChemokine (C-X-C Motif) Ligand 12ClinicalCold-Insoluble GlobulinsCollagenCrosslinkerCuesDataDefectDevelopmentDiameterDiffuseDihydroxyethanesEncapsulatedEndothelial CellsEngineeringEthanediolsEthylene GlycolsExcisionExperimental DesignsExtirpationFN1FailureFibronectin 1FibronectinsFibrosisFractureFundingGelGlycoprotein GP-2Grafting ProcedureHistologyHydrogelsImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodIn VitroIn vivo analysisInfectionInfiltrationKIAA0003LETS ProteinsLamininLarge External Transformation-Sensitive ProteinLeannessLigandsMMP2MMP2 geneMMPsMatrix MetalloproteinasesMediatingMesenchymal Progenitor CellMesenchymal Stem CellsMesenchymal progenitorMesenchymal stromal/stem cellsMiceMice MammalsMigration AssayMonoethylene GlycolMorbidityMorbidity - disease rateMurineMusNatural regenerationNerveOpsonic GlycoproteinOpsonic alpha(2)SB GlycoproteinOrgan TransplantationOrgan TransplantsOrthopedicOrthopedic Surgical ProfessionOrthopedicsPBSFParacrine CommunicationParacrine SignalingPatientsPeptidesPeriosteal CellPeriosteumPeriosteumsPre-B Cell Growth Stimulating FactorProceduresProcessProgenitor CellsPropertyReconstructive Surgical ProceduresRegenerationRemovalRoleSCYB12SDF-1SDF-1ASDF-1BSDF-1alphaSDF1SDF1ASDF1BSdf1 proteinSiteStromal Cell-Derived Factor 1Surgical RemovalTBE-1TLSF-ATLSF-BTPAR1TestingThinnessTissue EngineeringTissuesTorqueTransplantationTraumaTyr-Ile-Gly-Ser-ArgVEGFVEGFsValidationVascular Endothelial Growth FactorsVascularizationWorkYIGSRallogenic bone graftallogenic bone transplantationallograft bone transplantalpha 2-Surface Binding Glycoproteinautologous graftautotransplantationbioengineered tissuebiomechanicalbonebone allograftbone fracturebone reconstructionbone transplantcell typecellular transplantclinical translationclinically translatablecongenital anomalycontrast imagingcontrolled releasecrosslinkdesigndesigningdevelopmentalengineered tissueethylene glycolgraft healinghIRHhealingimplantationimprovedin vivoin vivo evaluationin vivo testinginnovateinnovationinnovativeknock-downknockdownmesenchymal stromal cellmesenchymal stromal progenitor cellsmesenchymal-derived stem cellsmetermimeticsorgan allograftorgan graftorgan xenograftosteoblast progenitorosteoblast stem cellosteogenic progenitorosteogenic stem cellosteoprogenitorosteoprogenitor celloverexpressoverexpressionparacrinepeptide mimeticpeptide mimicpeptidomimeticsreconstruction surgeryreconstructive surgeryrecruitregenerateregenerate bonerepairrepairedresectionresponsescRNA sequencingscRNA-seqshRNAshort hairpin RNAsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsmall hairpin RNAsocial rolestem cellsstromal cell-derived factor-1alphatransplanttyrosyl-isoleucyl-glycyl-seryl-argininevalidationsvascular
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

There are limited options for reconstruction of bone defects resulting from congenital anomalies, trauma,
infection, and oncologic resection. Over 2 million bone graft procedures are performed annually worldwide,

with the clinical ‘gold standard’ being the use of autografts. Autografts fully heal and integrate, mediated by the

periosteum, a thin layer of tissue and periosteal cells (PCs) surrounding bone. However, autografts are limited

due to tissue availability and donor site morbidity. Thus, decellularized allografts are commonly employed.

However, the limited ability of allografts, which lack periosteum, to remodel and integrate with the host tissue

directly contributes to ~35% and 60% failure rates within 2 and 10 years of implantation. Periosteal-mediated

healing is coordinated by a variety of contextual cues including matrix remodeling and adhesion and temporally

defined release of paracrine factors. Our overarching hypothesis is that allograft healing will be dramatically

improved by capturing critical healing cues in a tissue engineered periosteum (TEP). In the first funding cycle,

we pioneered development of the TEP, which incorporates mesenchymal stem cells (MSCs) and OPs within

hydrolytically degradable poly(ethylene glycol)(PEG)-based hydrogels, which are formed around allografts,

similar to native periosteum. TEP shows outstanding promise to enhance murine allograft healing, resulting in

a 300% increase in maximum fracture torque versus unmodified allografts at 9 weeks post-implantation.

However, healing was plagued by fibrotic tissue, which results in the allograft limited to ~50% of autograft

maximum torque. Fibrosis is consistent with poorly supported infiltration of TEP by host vessel/tissue, a

limitation resulting from bulk hydrolytic TEP degradation which results in structural insufficiencies to support

complete host-tissue infiltration. Thus, the focus of this renewal is a cellularly remodeled TEP, which enables

localized, cell-demanded degradation while maintaining bulk hydrogel properties to support host-tissue

infiltration. Three specific aims are outlined: Specific Aim 1: Tune TEP matrix cues (adhesive peptides and

MMP-degradable crosslinks) to coordinate tissue infiltration and improve allograft healing. Specific Aim 2:

Characterize TEP-mediated host-tissue recruitment. Specific Aim 3: Exploit the optimized TEP matrix to deliver

peptides emulating periosteal paracrine cues as a translatable, acellular TEP. Successful completion of these

Aims will significantly advance our understanding of how the periosteum coordinates allograft healing and the

design of engineered periosteum to promote these bone regeneration processes. The developed material

platforms and general approach are also readily applicable in other tissue engineering applications.

Grant Number: 5R01AR064200-09
NIH Institute/Center: NIH

Principal Investigator: Danielle Benoit

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Tissue Engineering Strategies to Revitalize Allografts — UNIVERSITY OF OREGON | UNITED STATES | Jul 2023 | Dev Procure